BackTrans Genic Overview

Trans Genic Current Assets

Latest current assets for 2342.T: $6.9B.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$6.88B
↑ 1.32% YoYΔ $89.80M vs prior year quarter

Peer trimmed avg / median

Loading

Trans Genic Current Assets History

Loading

Trans Genic vs. peers: Current Assets Comparison

Loading

Trans Genic Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Trans Genic (2342.T) FAQ

Trans Genic posts a current assets of $6.9B as of September 2026. That compares with $6.8B in the prior-year period — up 1.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Trans Genic's current assets was $6.8B. The latest reading is $6.9B — a 1.3% year-over-year increase (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Trans Genic's financial statement story. At $6.9B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 2342.T's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Trans Genic's other metric pages and overview cover the third.

Judging Trans Genic against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $6.9B here, then scan peer and history charts to see if the gap is persistent.

Questions & Answers